On the fly News and insights, exclusive to thefly.com

EVR

Evercore Partners

$76.89 /

-1.7 (-2.16%)

, SNY

Sanofi

$42.24 /

+0.13 (+0.31%)

10:06
08/14/19
08/14
10:06
08/14/19
10:06

Fly Intel: Top five analyst upgrades

Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Evercore Partners (EVR) upgraded to Neutral from Sell at Goldman Sachs with analyst Richard Ramsden saying believes that stronger U.S. large cap deal activity than he previously expected should support Evercore's revenues. 2. Sanofi (SNY) upgraded to Buy from Neutral at UBS with analyst Laura Sutcliffe saying she sees signs of a turnaround for the company and believes its pipeline can fixed ahead of patent expiration. 3. Bristol-Myers (BMY) upgraded to Overweight from Neutral at Atlantic Equities. 4. Horizon Pharma (HZNP) upgraded to Outperform from Market Perform at BMO Capital with analyst Gary Nachman citing the company's "strong" Q2 results driven by Krystexxa. 5. Ferrari (RACE) upgraded to Buy from Neutral at Goldman Sachs with analyst George Galliers citing the company's Q2 results earlier this month. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.

EVR

Evercore Partners

$76.89 /

-1.7 (-2.16%)

SNY

Sanofi

$42.24 /

+0.13 (+0.31%)

BMY

Bristol-Myers

$46.64 /

+0.17 (+0.37%)

HZNP

Horizon Therapeutics

$26.49 /

-0.07 (-0.26%)

RACE

Ferrari

$158.78 /

-2.31 (-1.43%)

  • 14

    Aug

  • 09

    Sep

  • 13

    Sep

  • 16

    Sep

  • 18

    Sep

  • 23

    Sep

  • 02

    Oct

EVR Evercore Partners
$76.89 /

-1.7 (-2.16%)

08/14/19 Goldman Sachs
Evercore Partners upgraded to Neutral from Sell at Goldman Sachs
06/06/19 Wolfe Research
Evercore Partners upgraded to Outperform from Peer Perform at Wolfe Research
05/23/19 JMP Securities
Evercore Partners upgraded to Outperform after 'advisory day' at JMP Securities
05/23/19 JMP Securities
Evercore Partners upgraded to Outperform from Market Perform at JMP Securities
SNY Sanofi
$42.24 /

+0.13 (+0.31%)

08/14/19 UBS
UBS upgrades Sanofi to Buy on turnaround prospects
08/14/19 UBS
Sanofi upgraded to Buy from Neutral at UBS
08/01/19 Wedbush
Lexicon price target lowered to $17 from $35 at Wedbush
07/30/19 Citi
Citi cuts Lexicon target to $3 from $15, still sees value in sotagliflozin
BMY Bristol-Myers
$46.64 /

+0.17 (+0.37%)

08/14/19 Atlantic Equities
Bristol-Myers upgraded to Overweight from Neutral at Atlantic Equities
08/09/19 William Blair
William Blair an 'aggressive' buyer of Nektar on today's 37% selloff
08/09/19 JPMorgan
Nektar downgraded to Neutral from Overweight at JPMorgan
08/09/19 Piper Sandler
Nektar price target lowered to $50 from $100 at Piper Jaffray
HZNP Horizon Therapeutics
$26.49 /

-0.07 (-0.26%)

08/14/19 BMO Capital
Horizon Pharma upgraded to Outperform from Market Perform at BMO Capital
07/10/19 Stifel
Horizon Pharma transition ahead of launch not reflected in shares, says Stifel
06/17/19 Jefferies
Horizon Pharma thinks two drugs can double sales, says Jefferies
05/23/19 Jefferies
Doctor survey suggests 'rapid uptake' for Horizon's teprotumumab, says Jefferies
RACE Ferrari
$158.78 /

-2.31 (-1.43%)

08/13/19 Goldman Sachs
Ferrari upgraded to Buy from Neutral at Goldman Sachs
08/05/19 Societe Generale
Ferrari upgraded to Buy from Hold at Societe Generale
07/18/19 BofA
Ferrari price target raised to $225 from $150 at BofA/Merrill
07/15/19 Goldman Sachs
Ferrari price target raised to $168 from $135 at Goldman Sachs

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.